Date: 2014-09-17
Type of information: Distribution agreement
Compound: OncoDEEP DX and Clinical cancer panels
Company: OncoDNA (Belgium) Istomedica (Greece)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On September 17, 2014, OncoDNA , the Belgian cancer theranostic company, which performs DNA next generation sequencing (NGS) and classical immunohistochemistry to provide oncologists with drug treatment recommendations, has finalized a distribution agreement with Istomedica, a leading pathology laboratory in Greece to bring affordable and state-of-the-art theranostic analyses to
the Greek population. Istomedica has chosen OncoDNA as its preferred supplier of clinical grade molecular theranostic using the OncoDEEP DX and Clinical cancer panels in combination with the package PLUS, a cancer specific package of different IHCs and other tests like FISH,
methylation, etc The collaboration agreement with OncoDNA will enable Greek physicians to access medical innovations based on next gen sequencing, providing them with clinically relevant interpretations of patients\' tumours by using the OncoSHARE web platform designed
by OncoDNA. This collaboration agreement confers exclusivity in Greece on Istomedica. This is the second exclusive agreement granted by OncoDNA.
Financial terms:
Latest news:
